Literature DB >> 24746146

Antibody humanization methods for development of therapeutic applications.

Vahideh Ahmadzadeh1, Safar Farajnia, Mohammad Ali Hosseinpour Feizi, Ramezan Ali Khavari Nejad.   

Abstract

Recombinant antibody technologies are rapidly becoming available and showing considerable clinical success. However, the immunogenicity of murine-derived monoclonal antibodies is restrictive in cancer immunotherapy. Humanized antibodies can overcome these problems and are considered to be a promising alternative therapeutic agent. There are several approaches for antibody humanization. In this article we review various methods used in the antibody humanization process.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24746146     DOI： 10.1089/mab.2013.0080

Source DB:  PubMed          Journal:  Monoclon Antib Immunodiagn Immunother        ISSN： 2167-9436


  15 in total

1.  VH-VL orientation prediction for antibody humanization candidate selection: A case study.

Authors:  Alexander Bujotzek; Florian Lipsmeier; Seth F Harris; Jörg Benz; Andreas Kuglstatter; Guy Georges
Journal:  MAbs       Date:  2016       Impact factor: 5.857

2.  Design and Generation of Humanized Single-chain Fv Derived from Mouse Hybridoma for Potential Targeting Application.

Authors:  Kannika Khantasup; Warangkana Chantima; Chak Sangma; Kanokwan Poomputsa; Tararaj Dharakul
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2015-12

Review 3.  Immunology proves a great success for treating systemic autoimmune diseases - a perspective on immunopharmacology: IUPHAR Review 23.

Authors:  Masaru Ishii
Journal:  Br J Pharmacol       Date:  2017-04-24       Impact factor: 8.739

Review 4.  Peptide aptamers: development and applications.

Authors:  Sergey Reverdatto; David S Burz; Alexander Shekhtman
Journal:  Curr Top Med Chem       Date:  2015       Impact factor: 3.295

5.  Antibody Preparations from Human Transchromosomic Cows Exhibit Prophylactic and Therapeutic Efficacy against Venezuelan Equine Encephalitis Virus.

Authors:  Christina L Gardner; Chengqun Sun; Thomas Luke; Kanakatte Raviprakash; Hua Wu; Jin-An Jiao; Eddie Sullivan; Douglas S Reed; Kate D Ryman; William B Klimstra
Journal:  J Virol       Date:  2017-06-26       Impact factor: 5.103

6.  Therapeutic Antibodies: An Overview.

Authors:  Gunnar Houen
Journal:  Methods Mol Biol       Date:  2022

7.  Effective in vivo therapeutic IgG antibody against VP3 of enterovirus 71 with receptor-competing activity.

Authors:  Qiang Jia; Qingyong Ng; Wenjie Chin; Tao Meng; Vincent Tak Kwong Chow; Cheng-I Wang; Jimmy Kwang; Fang He
Journal:  Sci Rep       Date:  2017-04-19       Impact factor: 4.379

8.  Potent Neutralizing Humanized Antibody With Topical Therapeutic Potential Against HPV18-Related Cervical Cancer.

Authors:  Bilian Huang; Linjing Zhu; Hongxia Wei; Haixia Shi; Doudou Zhang; Huanyun Yuan; Linlin Luan; Nan Zheng; Shijie Xu; Waqas Nawaz; Ying Hong; Xilin Wu; Zhiwei Wu
Journal:  Front Immunol       Date:  2021-06-24       Impact factor: 7.561

9.  Development of Germline-Humanized Antibodies Neutralizing Botulinum Neurotoxin A and B.

Authors:  Sebastian Miethe; Christelle Mazuet; Yvonne Liu; Robert Tierney; Christine Rasetti-Escargueil; Arnaud Avril; André Frenzel; Philippe Thullier; Thibaut Pelat; Remi Urbain; Alexandre Fontayne; Dorothea Sesardic; Michael Hust; Michel Robert Popoff
Journal:  PLoS One       Date:  2016-08-25       Impact factor: 3.240

Review 10.  The European AntibotABE Framework Program and Its Update: Development of Innovative Botulinum Antibodies.

Authors:  Christine Rasetti-Escargueil; Arnaud Avril; Sebastian Miethe; Christelle Mazuet; Yagmur Derman; Katja Selby; Philippe Thullier; Thibaut Pelat; Remi Urbain; Alexandre Fontayne; Hannu Korkeala; Dorothea Sesardic; Michael Hust; Michel R Popoff
Journal:  Toxins (Basel)       Date:  2017-10-02       Impact factor: 4.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.